公开(公告)号：US20060269557A1

公开(公告)日：2006-11-30

申请号：US11432304

申请日：2006-05-10

申请人： Mark Sherman ,  Anna Wu ,  Robert Reiter

发明人： Mark Sherman ,  Anna Wu ,  Robert Reiter

IPC分类号： A61K39/395 ,  C07H21/04 ,  C12P21/06 ,  C12N5/06 ,  C07K14/52 ,  C07K16/30 ,  C07K16/46

CPC分类号： C07K16/3069 ,  A61K2039/505 ,  C07K2317/24 ,  C07K2317/565

摘要： Prostate stem cell antigen (PSCA) is expressed in the majority of prostate cancer patients, making it an ideal target for cancer immunotherapy. Murine monoclonal antibody 1G8 binds to PSCA with nanomolar affinity, but its efficacy as a therapeutic agent is limited by the generation of a HAMA response. The present invention discloses humanized 1G8 antibodies in which the majority of the mouse-derived epitopes have been removed. These humanized antibodies bind PSCA with high affinity and specificity, and have been shown to reduce human bladder tumor take in a nude mouse model. These characteristics make the humanized antibodies of the present invention attractive agents for the treatment and detection of tumors expressing PSCA.

公开(公告)号：US20080069816A1

公开(公告)日：2008-03-20

申请号：US11861093

申请日：2007-09-25

申请人： Paul Yazaki ,  Mark Sherman ,  John Shively ,  Andrew Raubitschek ,  Anna Wu

发明人： Paul Yazaki ,  Mark Sherman ,  John Shively ,  Andrew Raubitschek ,  Anna Wu

IPC分类号： A61K39/395 ,  A61P35/00

CPC分类号： C07K16/3007 ,  A61K2039/505 ,  C07K16/32 ,  C07K16/465 ,  C07K2317/24 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/567 ,  C07K2317/626 ,  C07K2317/92 ,  C12N15/1089 ,  G01N33/574

摘要： Embodiments of the present invention utilize a more efficient CDR grafting technique to generate humanized versions of the T84.66 antibody. The technique used to generate these antibodies utilizes crystallographic structural data to select an immunoglobulin framework having maximum structural overlap with a non-human donor molecule. This technique was used to develop humanized T84.66 antibodies exhibiting in vitro binding affinity and specificity for carcinoembryonic antigen (CEA) nearly identical to that of T84.66 and the ability to specifically target tumors expressing CEA in vivo.

摘要翻译： 本发明的实施方案利用更有效的CDR移植技术来产生人源化版本的T84.66抗体。 用于产生这些抗体的技术利用晶体结构数据来选择与非人供体分子具有最大结构重叠的免疫球蛋白框架。 该技术用于开发显示与T84.66几乎完全相同的癌胚抗原（CEA）的体外结合亲和性和特异性的人源化T84.66抗体，并且具体靶向体内表达CEA的肿瘤的能力。

公开(公告)号：US20050244333A1

公开(公告)日：2005-11-03

申请号：US11077978

申请日：2005-03-11

申请人： Paul Yazaki ,  Mark Sherman ,  John Shively ,  Andrew Raubitschek ,  Anna Wu

发明人： Paul Yazaki ,  Mark Sherman ,  John Shively ,  Andrew Raubitschek ,  Anna Wu

IPC分类号： A61K39/395 ,  A61K51/00 ,  C07K16/30 ,  C12N15/10 ,  G01N33/574

CPC分类号： C07K16/3007 ,  A61K2039/505 ,  C07K16/32 ,  C07K16/465 ,  C07K2317/24 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/567 ,  C07K2317/626 ,  C07K2317/92 ,  C12N15/1089 ,  G01N33/574

摘要： Embodiments of the present invention utilize a more efficient CDR grafting technique to generate humanized versions of the T84.66 antibody. The technique used to generate these antibodies utilizes crystallographic structural data to select an immunoglobulin framework having maximum structural overlap with a non-human donor molecule. This technique was used to develop humanized T84.66 antibodies exhibiting in vitro binding affinity and specificity for carcinoembryonic antigen (CEA) nearly identical to that of T84.66 and the ability to specifically target tumors expressing CEA in vivo.

摘要翻译： 本发明的实施方案利用更有效的CDR移植技术来产生人源化版本的T84.66抗体。 用于产生这些抗体的技术利用晶体结构数据来选择与非人供体分子具有最大结构重叠的免疫球蛋白框架。 该技术用于开发显示与T84.66几乎完全相同的癌胚抗原（CEA）的体外结合亲和性和特异性的人源化T84.66抗体，并且具体靶向体内表达CEA的肿瘤的能力。

公开(公告)号：US20070280882A1

公开(公告)日：2007-12-06

申请号：US11741253

申请日：2007-04-27

申请人： Anna Wu ,  Tove Olafsen ,  Andrew Raubitschek

发明人： Anna Wu ,  Tove Olafsen ,  Andrew Raubitschek

IPC分类号： A61K39/395 ,  A61K49/00 ,  A61K51/00 ,  A61P37/00 ,  C07K16/00

CPC分类号： C07K16/2887 ,  A61K51/1027 ,  C07K2317/622 ,  C07K2319/30

摘要： The present invention provides anti-CD20 antibody fragments for use as in vivo imaging probes and as therapeutic moieties for the diagnosis and treatment of NHL.

摘要翻译： 本发明提供用作体内成像探针的抗CD20抗体片段和用于诊断和治疗NHL的治疗部分。

公开(公告)号：US09747278B2

公开(公告)日：2017-08-29

申请号：US13403893

申请日：2012-02-23

申请人： Eric A. Bier ,  Anna Wu

发明人： Eric A. Bier ,  Anna Wu

IPC分类号： G06F17/30 ,  G06F17/27

CPC分类号： G06F17/278 ,  G06F17/30241

摘要： A system and method for mapping text phrases to geographical locations is provided. Entities, each comprising one of a location, person, and place, are identified in one or more documents. Possible candidate locations associated with each entity are determined. An initial score is assigned to each location. The initial scores are adjusted and the candidate location with the highest adjusted score is selected for each entity. The selected candidate location is applied to all occurrences of the entity in the documents.

公开(公告)号：US20130226928A1

公开(公告)日：2013-08-29

申请号：US13403893

申请日：2012-02-23

申请人： Eric A. Bier ,  Anna Wu

发明人： Eric A. Bier ,  Anna Wu

IPC分类号： G06F17/30

CPC分类号： G06F17/278 ,  G06F17/30241

摘要： A system and method for mapping text phrases to geographical locations is provided. Entities, each comprising one of a location, person, and place, are identified in one or more documents. Possible candidate locations associated with each entity are determined. An initial score is assigned to each location. The initial scores are adjusted and the candidate location with the highest adjusted score is selected for each entity. The selected candidate location is applied to all occurrences of the entity in the documents.

摘要翻译： 提供了一种将文本短语映射到地理位置的系统和方法。 在一个或多个文档中标识了各自包含位置，人物和地点之一的实体。 确定与每个实体相关联的可能候选位置。 初始分数分配给每个位置。 调整初始分数，并为每个实体选择具有最高调整分数的候选位置。 选择的候选位置应用于文档中实体的所有出现。

公开(公告)号：US06410319B1

公开(公告)日：2002-06-25

申请号：US09421295

申请日：1999-10-20

申请人： Andrew Raubitschek ,  Anna Wu ,  Michael C. Jensen

发明人： Andrew Raubitschek ,  Anna Wu ,  Michael C. Jensen

IPC分类号： C12N506

CPC分类号： C07K16/2887 ,  A61K2035/124 ,  A61K2039/505 ,  C07K14/7051 ,  C07K2317/52 ,  C07K2317/622 ,  C07K2319/00 ,  C12N5/0636 ,  C12N2502/30 ,  C12N2510/00

摘要： Genetically engineered, CD20-specific redirected T cells expressing a cell surface protein-having an extracellular domain comprising a receptor which is specific for CD20, an intracellular signaling domain, and a transmembrane domain. Use of such cells for cellular immunotherapy of CD20+ malignancies and for abrogating any untoward B cell function. In one embodiment, the cell surface protein is a single chain FvFc:&zgr; receptor where Fv designates the VH and VL chains of a single chain monoclonal antibody to CD20 linked by peptide, Fc represents a hinge-CH2-CH3 region of a human IgG1, and &zgr; represents the intracellular signaling domain of the zeta chain of human CD3. A method of making a redirected T cell expressing a chimeric T cell receptor by electroporation using naked DNA encoding the receptor.

摘要翻译： 遗传工程化的CD20特异性重定向T细胞，其表达具有胞外结构域的细胞表面蛋白，其包含对CD20特异性的受体，细胞内信号结构域和跨膜结构域。 使用此类细胞进行CD20 +恶性肿瘤的细胞免疫治疗，并消除任何不良B细胞功能。 在一个实施方案中，细胞表面蛋白是单链FvFc： 受体，其中Fv表示通过肽连接的CD20单链单克隆抗体的VH和VL链，Fc表示人IgG1的铰链-CH2-CH3区， 表示人CD3的zeta链的细胞内信号结构域。 通过使用编码受体的裸DNA通过电穿孔制备表达嵌合T细胞受体的重定向T细胞的方法。